【與漢康讀懂腫瘤免疫新藥的抗癌革命】由漢康生技企劃製作

當一顆藥在實驗室裡完美無瑕，為什麼進入工廠卻可能全盤崩潰？
當專利保護的是「藥是什麼」，那麼誰在守護「藥怎麼做出來」？
當全球多功能蛋白不到 1.6% 能成功走入臨床，漢康如何跨越放大生產的死亡之谷？
本集我們邀請到漢康生技 CMC 舵手——執行總監 郭孟薇 博士（Vivian），深入解析從 DNA 到 IND 僅 13 個月背後的工藝革命。

精彩內容：

• CMC 的商業底層邏輯： 為什麼國際 Big Pharma 買的是「確定性」而不是「可能性」？

• 授權金背後的關鍵籌碼： 為什麼成熟的 CMC 數據包能直接拉高國際談判桌上的估值？

• 死亡之谷的真相： 為何細胞從杯子大小放大到上萬公升反應槽時，失敗風險會指數級上升？

• 99% 純度的意義： 當法規前期 90% 即可接受，漢康為何選擇在第一階段就做到接近上市等級？

• 成本與病患的平衡點： 高產量（3–6 g/L）與高回收率如何同時壓低定價並維持健康毛利？

【About This Episode】
When a drug performs flawlessly in the lab, why can it collapse during scale-up?
If patents protect what a drug is, who protects how it is made?
And when fewer than 1.6% of tri-functional biologics make it to clinical stage, how does HanchorBio cross the so-called “valley of death”?
In this episode, Dr. Vivian Kuo, Head of CMC at HanchorBio, reveals the industrial strategy behind achieving >99% purity, 3–6 g/L yield, multi-year stability, and a rapid 13-month timeline from DNA to IND.
CMC is not just manufacturing—it is the second moat that determines whether a promising molecule becomes a global medicine.

【Key Takeaways】
The Commercial Logic of CMC: Why do global pharmaceutical giants buy certainty instead of possibility?
Licensing Leverage: How can a robust CMC package significantly increase valuation at the negotiation table?
The Valley of Death in Scale-Up: Why does moving from lab-scale to industrial bioreactors dramatically increase the risk of failure?
What 99% Purity Really Means: Why exceed early-stage regulatory requirements and aim for near-commercial standards from day one?
Balancing Affordability and Profitability: How do high yield and high recovery rates enable both accessible pricing and sustainable margins?

漢康生技官網：https://www.hanchorbio.com/
漢康生技LinkedIn：https://reurl.cc/7b19y9

本節目旨在透過科學導讀與商業邏輯分享，幫助聽眾理解生技產業趨勢與漢康生技之核心價值。所有臨床數據均以公司正式發布之公告為準，內容不構成任何形式之投資建議。以上內容為創辦人基於產業經驗對產品潛力的評估，不代表公司對未來股價或獲利的保證。